Amgen (Nasdaq:AMGN) is a biotechnology company with blockbuster products like Neupogen, Enbrel and Repatha. It has a market cap of $135.4 bn, a price to earnings ratio of 16.88 and a dividend yield of 2.48 per cent. Guest Nesan Nair, Sasfin Securities and resident expert Paul Theron from Vestact decide whether Amgen is hot or not.